Compare LGO & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGO | THAR |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.8M | 82.7M |
| IPO Year | 2007 | 2022 |
| Metric | LGO | THAR |
|---|---|---|
| Price | $0.95 | $2.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.30 | N/A |
| AVG Volume (30 Days) | ★ 377.3K | 340.9K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $111,884,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $53.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $0.95 |
| 52 Week High | $2.70 | $9.08 |
| Indicator | LGO | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 42.90 |
| Support Level | $0.88 | $2.20 |
| Resistance Level | $1.11 | $2.57 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 26.98 | 30.91 |
Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.